Berger, Mark S <br/><br/>
Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse.  [electronic resource] 

 -  Investigational new drugs  Nov 2002 
 - 395-406 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0167-6997 
<br/><br/><label>Standard No.: </label>10.1023/a:1020658028082  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aminoglycosides<br/>Anti-Bacterial Agents--adverse effects<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Clinical Trials as Topic--statistics & numerical data<br/>Gemtuzumab<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Licensure<br/>Middle Aged<br/>Secondary Prevention<br/>Survival Rate<br/>United States<br/>United States Food and Drug Administration--legislation & jurisprudence